Guanoxan
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H13N3O2 |
Molar mass | 207.233 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Guanoxan is a sympatholytic drug that was marketed as Envacar by Pfizer in the UK to treat high blood pressure. It was not widely used and was eventually withdrawn from the market due to liver toxicity.[1][2]
References
- ^ Broadley KJ (1996). Autonomic Pharmacology. CRC Press. p. 276. ISBN 9780748405565.
- ^ Wardell WM, Lasagna L (1975). Regulation and drug development. Washington: American Enterprise Institute for Public Policy Research. p. 65. ISBN 9780844731674.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles with changed ChemSpider identifier
- Articles with changed InChI identifier
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Adrenergic release inhibitors
- Benzodioxans
- Guanidines
- Hepatotoxins
- Withdrawn drugs
- All stub articles
- Antihypertensive agent stubs